Table 4.
Association of gene polymorphisms with treatment-related toxicity
| Treatment Arm | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NT | 5-FU/RT | mFOLFOX-6 | |||||||
| Gene polymorphism |
Patients n=132 |
Grade ≥3 AE n=27 |
p-value | Patients n=132 |
Grade ≥3 AE n=24 |
p-value | Patients n=80 |
Grade ≥3 AE n=9 |
p-value |
| XRCC1 R399Q | |||||||||
| R399 alone | 40 | 2 (5%) | 0.003 | 40 | 2 (5%) | 0.01 | 17 | 0 (0%) | 0.10 |
| Q399 | 92 | 25 (27%) | 92 | 22 (24%) | 63 | 9 (14%) | |||
| XPD K751Q | |||||||||
| K751 alone | 55 | 17 (31%) | 0.02 | 55 | 15 (27%) | 0.02 | 32 | 6 (19%) | 0.08 |
| Q751 | 77 | 11 (14%) | 77 | 9 (12%) | 48 | 3 (6%) | |||
| TP53 R72P | |||||||||
| R72 alone | 95 | 15 (16%) | 0.05 | 95 | 14 (15%) | 0.10 | 57 | 3 (5%) | 0.008 |
| P72 | 37 | 12 (32%) | 37 | 10 (27%) | 23 | 6 (26%) | |||
AE: Adverse events; 5-FU: 5-fluorouracil; RT: Radiotherapy; NT: neoadjuvant chemoradiation therapy; mFOLFOX-6: Modified FOLFOX-6 chemotherapy